Digital Health Global
MARCH 29, 2023
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Digital Health Global
NOVEMBER 30, 2023
Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drug development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healthcare IT Today
NOVEMBER 14, 2022
AngelEye Health’s relationship approach has differentiated it in the market and presents a compelling value proposition to hospitals, improves family satisfaction and enhances patient outcomes. Within Life Sciences, the firm focuses on MedTech, Diagnostics, and Opportunistic Drug Development. About SeedtoB.
Lloyd Price
FEBRUARY 18, 2024
The HealthTech M&A landscape currently presents both challenges and opportunities for "soft landing" deals, where the acquiring company integrates the target without significant disruption. Develop personalized medicine approaches. Ultimately, the approach will depend on the specific circumstances of each deal.
The Digital Health Corner
MARCH 26, 2018
Blockchain technology’s potential impact on the life sciences industry (drug development, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain. Patients relocating also present an obstacle to tracking devices already implanted.
Expert insights. Personalized for you.
167 
Let's personalize your content